

Treatment Naïve

Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3  
**C-SWIFT**


Poordad F, et al. EASL 2015; Abstract O006.

# Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve GT 1 or 3 C-SWIFT Study: Features

## C-SWIFT Trial

- **Design:** Open-label phase 2 trial to evaluate the efficacy and safety of short duration therapy with elbasvir-grazoprevir + sofosbuvir in treatment-naïve GT 1 or 3 infection, with or without cirrhosis
- **Entry Criteria**
  - Chronic HCV Genotype 1 (n=102) or Genotype 3 (n=41)
  - 18 years or older
  - No prior HCV treatment
  - HCV RNA  $\geq 10,000$  IU/ml
  - ALT and AST  $< 350$  IU/L
  - Cirrhosis allowed
- **Primary End-Point:** SVR12

# Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve GT 1 or 3 C-SWIFT Study: Study Design for GT 1




**Abbreviations:** EBR-GZR = elbasvir-grazoprevir; SOF = sofosbuvir

## Drug Dosing

Elbasvir-grazoprevir (50/100 mg): fixed-dose combination; one pill once daily

Sofosbuvir: 400 mg once daily

# Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve GT 1 or 3 C-SWIFT Study: Study Design for GT 3



**Abbreviations:** EBR-GZR= grazoprevir-elbasvir; SOF = sofosbuvir

## Drug Dosing

Grazoprevir/elbasvir (100/50 mg): fixed dose combination; one pill once daily

Sofosbuvir 400 mg once daily


# Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve GT 1 or 3 C-SWIFT Study: Baseline Characteristics

Baseline Characteristic	Genotype 1				Genotype 3		
	No cirrhosis		Cirrhosis		No Cirrhosis		Cirrhosis
	4 weeks N=31	6 weeks N=30	6 weeks N=20	8 weeks N=21	8 weeks N=15	12 weeks N=14	12 weeks N=12
Mean age, years	52	51	56	57	51	42	55
Male sex, %	65	63	65	62	73	57	83
Race, %							
White	97	93	100	95	100	100	100
Hispanic/Latino	29	47	65	48	40	57	50
HCV Genotype, %							
1a	84	87	80	76	--	--	--
1b	16	13	20	24	--	--	--
3	--	--	--	--	100	100	100
IL28B CC, %	36	27	30	24	40	21	50
Cirrhosis, %	0	0	100	100	0	0	100
HCV RNA, 10 <sup>6</sup> IU/ml (mean)	3.7	3.1	1.7	2.4	3.3	2.6	2.3

Source: Poordad F, et al. EASL 2015; Abstract O006.

# Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve GT 1 or 3 C-SWIFT Study: Results for GT 1


## C-SWIFT: SVR 12\* for GT 1 by Treatment Duration and Cirrhosis



\*Analysis by modified intention-to-treat analysis (excluded patients who discontinued due to reasons other than virologic failure)

# Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve GT 1 or 3 C-SWIFT Study: Results for GT 3

## C-SWIFT: SVR 12\* for GT 3 by Treatment Duration and Cirrhosis



Analysis by modified intention-to-treat analysis (excluded patients who discontinued due to reasons other than virologic failure)

# Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve GT 1 or 3 C-SWIFT Study: Conclusions

**Conclusions:** “A novel regimen of grazoprevir/elbasvir with sofosbuvir was able to shorten treatment duration to 8 weeks or less among cirrhotic and non-cirrhotic HCV genotype 1-infected patients.”  
“Genotype 3 patients achieved high SVR12 rates with 8-12 weeks of therapy, including patients with cirrhosis.”